Physician profile
Angelo Sermas
NPI 1891750592
$5,546.85
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.17 · 2020: $18.35 · 2021: $143 · 2022: $1,045 · 2023: $2,909 · 2024: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323 · Education: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.48 |
| Education | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.49 | 2022-2024 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $645.07 | 2022-2024 | Emgality, Reyvow |
| Pfizer INC. | $463.66 | 2023-2024 | |
| Boston Scientific Corporation | $444.83 | 2023-2024 | Vercise |
| Novartis Pharmaceuticals Corporation | $421.26 | 2022-2024 | |
| Ucb, INC. | $410.87 | 2022-2024 | Briviact, Nayzilam |
| Sk Life Science, INC. | $409.00 | 2022-2024 | Xcopri |
| Lundbeck LLC | $219.12 | 2023-2024 | Rexulti, Vyepti |
| Amneal Pharmaceuticals LLC | $212.11 | 2022-2024 | Rytary |
| Genentech USA, INC. | $183.44 | 2023-2024 | Ocrevus |
| Biohaven Pharmaceuticals, INC. | $124.40 | 2021 | |
| Acadia Pharmaceuticals INC | $114.15 | 2023-2024 | Nuplazid |
| Corium, LLC | $67.43 | 2023 | Adlarity |
| Emd Serono, INC. | $53.83 | 2019-2024 | |
| Argenx US, INC. | $52.19 | 2023 | Vyvgart, Vyvgart Hytrulo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $42.79 | 2024 | |
| Amgen INC. | $42.00 | 2023 | Aimovig |
| Abbott Laboratories | $36.58 | 2024 | Infinity |
| Sunovion Pharmaceuticals INC. | $34.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.96 | 2022 | |
| Insightec,INC | $27.94 | 2023-2024 | Exablate |
| Otsuka America Pharmaceutical, INC. | $22.93 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.37 | 2023 | Austedo |
| Sumitomo Pharma America, INC. | $19.34 | 2023 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2021 | |
| Livanova USA, INC. | $18.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Sermas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.